Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Oral proteasome inhibitor with strong preclinical efficacy in myeloma models

Fig. 1

Inhibition of non-proteasomal proteases. 10 μM of proteasome inhibitor compounds were tested with a panel of proteases, Cathepsin G (serine protease with P1 specificity of phenylalanine/leucine/tyrosine), Elastase (neutrophil serine protease with P1 specificity of valine), Cathepsin B (cysteine protease), Renin (aspartate protease), and ACE (metalloprotease angiotensin converting enzyme). Percent inhibition was calculated based on compound’s effect on protease activity subtracted with a substrate control without an enzyme

Back to article page